![]() The use of non-myeloablative, immunosuppressive conditioning regimens, also known as reduced-intensity conditioning (RIC) regimens, offers the opportunity to achieve full-donor engraftment with reduced transplant-related complications and mortality, thus, enabling also patients of advanced age and with co-morbidities to receive allografting. Data from experimental animal models as well as from preliminary clinical trials suggested that a GVT effect, analogous to the GVL effect, may be generated against solid tumors such as breast cancer, renal cell cancer, and other malignancies. The graft-versus-leukemia (GVL) effect is an important component of the therapeutic effect of allogeneic HSCT. Storb et al (2003) stated that the allogeneic graft-versus-tumor (GVT) effects observed in patients who received HSCT for hematological malignancies have stimulated trials of allogeneic HSCT in patients with refractory metastatic solid tumors. This approach arose from studies that allogeneic HSCT has been successfully employed for patients with aplastic anemia and hemoglobinopathies. The use of hematopoietic stem cell transplant (HSCT) has been investigated for the treatment of selected solid tumors. While some solid tumors are very chemo-radiosensitive (e.g., Ewing’s sarcoma and gonadal tumors) as a whole they are not curable by chemotherapy. Solid tumors (also known as solid neoplasms) in adults represent a heterogeneous group of malignancies that encompass various body systems. Malignant neoplasm without specification of site Malignant poorly differentiated neuroendocrine tumors Malignant neoplasm of kidney and other and unspecified urinary organs Malignant neoplasm of female and male breast Malignant neoplasm of peripheral nerves, autonomic nervous system, connective and soft tissue Malignant neoplasm trachea, bronchus, and lung Malignant neoplasm of accessory sinuses (paranasal) Malignant neoplasm of gall bladder and other and unspecified parts of biliary tract Malignant neoplasm of rectosigmoid junction, rectum, anus and anal canal ICD-10 codes not covered for indications listed in the CPB (not all-inclusive): Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system Malignant neoplasm of bone and articular cartilage of other and unspecified sites ICD-10 codes covered if selection criteria are met (not all-inclusive): HCPCS codes not covered for indications listed in the CPB:Ĭord blood-derived stem cell transplantation allogeneicīone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation and related complications including: pheresis and cell preparations/storage marrow ablative therapy drugs, supplies, hospitalization with outpatient follow-up medical/surgical diagnostic emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition Hematopoietic progenitor cell (HPC) allogeneic transplantation per donor Transplant preparation of hematopoietic progenitor cells cryopreservation and storageīone marrow harvesting for transplantation allogenic Management of recipient hematopoietic progenitor cell donor search and cell acquistionīlood-derived hematopoietic progenitor cell harvesting for transplantation, per collection allogenic Codes requiring a 7th character are represented by "+":ĬPT codes not covered for indications listed in the CPB: Information in the below has been added for clarification purposes. Table: CPT Codes / HCPCS Codes / ICD-10 Codes Code
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |